Navigation Links
FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
Date:11/30/2007

INDIANAPOLIS, Nov. 30 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Cymbalta(R) (duloxetine HCl) for the maintenance treatment of major depressive disorder (MDD) in adults.

"Relapse, the re-emergence of depressive symptoms after a successful treatment of depression, is a significant clinical concern," says Doug Williamson, M.D., Cymbalta associate medical director for Eli Lilly and Company. "This approval from the FDA is important because data from our Cymbalta clinical trial demonstrate that continuing to treat the patient delays the time to possible relapse."

Treating the broad range of depression symptoms may minimize the presence of residual symptoms (e.g., anxiety, guilt and low self-esteem) and can help delay the time to relapse(1). Common symptoms of depression can include sadness, loss of interest, fatigue, changes in appetite or weight, or bodily aches and pains.

"Once an episode of depression has been successfully treated, it is imperative that the symptoms do not return," said Lauren Marangell, M.D., an internationally recognized expert on depression and other mood disorders and a distinguished scholar at Lilly. "The American Psychiatric Association has recommended maintenance of antidepressant treatment to help decrease the chance of relapse."

The efficacy and safety of Cymbalta for maintenance treatment of major depression was established in a double-blind, placebo-controlled clinical trial. Patients with major depression in the trial (533 patients) received Cymbalta 60 mg once daily. After 12 weeks, 278 patients met the criteria for entering the continuation phase and were randomly assig
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)..., , NEW YORK, Nov. 20 Re...h report is available in its catalogue. ,, Blo...ts - A World Market Analysis ,, http://www.r...--Measurement-Instruments---A-World-Market-Analysi...;utm_campaign=prnewswire ,, Measurement of bl...
(Date:11/20/2009)..., , NEW YORK, Nov. 20 ,...esearch report is available in its catalogue. ,...,, http://www.reportlinker.com/p0164741/Globa...source=prnewswire&utm_medium=pr&utm_campai...t biopsy devices includes the spring loaded core n...
(Date:11/20/2009)..., , MINNEAPOLIS, Nov. 20 /PRNewswire-FirstCall...ced results for its first quarter ended September ...er diluted share, on revenues of $3,263,000. This...r diluted share, on revenues of $3,168,000 for the...he first quarter results, Biotel President and CEO...
Breaking Medicine Technology:Reportlinker Adds Blood Pressure Monitoring & Measurement Instruments - A World Market Analysis 2Reportlinker Adds Blood Pressure Monitoring & Measurement Instruments - A World Market Analysis 3Reportlinker Adds Blood Pressure Monitoring & Measurement Instruments - A World Market Analysis 4Reportlinker Adds Blood Pressure Monitoring & Measurement Instruments - A World Market Analysis 5Reportlinker Adds Blood Pressure Monitoring & Measurement Instruments - A World Market Analysis 6Reportlinker Adds Blood Pressure Monitoring & Measurement Instruments - A World Market Analysis 7Reportlinker Adds Blood Pressure Monitoring & Measurement Instruments - A World Market Analysis 8Reportlinker Adds Blood Pressure Monitoring & Measurement Instruments - A World Market Analysis 9Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2Biotel Announced Profitable First Quarter Ended September 30, 2009 2Protein critical for insulin secretion may be contributor to diabetes 60082 1Protein critical for insulin secretion may be contributor to diabetes 60082 2Protein critical for insulin secretion may be contributor to diabetes 60082 3NSF grant supports Rutgers Camden program for science majors 10524 1NSF grant supports Rutgers Camden program for science majors 10524 2NSF grant supports Rutgers Camden program for science majors 10524 3Breast Abnormality Follow Up Often Later in Black Women 60080 1Breast Abnormality Follow Up Often Later in Black Women 60080 2
...art Association rapid access journal report: , , ...stimates more than 11 million older Americans coul... from the JUPITER trial are adopted into guideline...lts eligible for statin therapy to over 44 million...alysis highlights a public health challenge since,...
...Jan. 13 MannKind Corporation (Nasdaq: MNKD ) ... to demonstrate equivalence of its commercial inha...clinical trials to deliver AFRESA(TM), MannKind,s ... Phase 3 clinical trials. , , Study 138 - Bioeq...s , , Study 138 compared the bioequivalence of M...
Other Medicine Technology:New Analysis Estimates Numbers of Older U.S. Adults Who May Benefit From Statin Therapy 2New Analysis Estimates Numbers of Older U.S. Adults Who May Benefit From Statin Therapy 3New Analysis Estimates Numbers of Older U.S. Adults Who May Benefit From Statin Therapy 4New Analysis Estimates Numbers of Older U.S. Adults Who May Benefit From Statin Therapy 5MannKind Reports Successful Completion of Device Bioequivalence Trial 2MannKind Reports Successful Completion of Device Bioequivalence Trial 3
(Date:11/20/2009)... , Pioneering Neurologist Closer to Understandi.... 20 Dr. Jeremy Schmahm...ool and neurologist at the Massachusetts General H...nted his laboratory,s research on the new field of...MINDlink Foundation. ,, Dr. Schmahmann is an aw...
(Date:11/20/2009)... , WASHINGTON, Nov. 20 /PRNewswire-USNewswire...ng senators to modify health care reform legislati... regarding a health insurance individual coverage ...enforceable mandate will minimize adverse selectio...rules prescribed by the bill. ,, "The individua...
(Date:11/20/2009)... , QUINCY, Mass., Nov. 20 Follo...rmarket Company removed from sale Shedd,s Country ...ice and Shedd,s Country Crock ® Side Dishes D...te allergen. ,, The following code dates and U...74; Side Dishes DELUXE Cheddar Broccoli Rice 21 oz...
(Date:11/20/2009)... , MADISON, N.J., Nov. 20 /PRNewswire-FirstC...nza virus may have peaked in late October, but the...urce of illness in all age groups, including the e...tics Incorporated (NYSE: DGX ), the world,s lead...d services. ,, In its most recent Quest Diagno...
(Date:11/20/2009)... , ST. LOUIS, Nov. 20 /PRNewswire-FirstCall/...ounced that it will present at the Bank of America...December 2-3, 2009, at the Crowne Plaza Hotel Time...ent Wednesday, December 2nd at 8:30 a.m. Eastern T...cess a live, audio webcast of Centene,s presentati...
Breaking Medicine News(10 mins):Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3
.... 14 MAKO Surgical Corp., a,developer of minimall...chnology for knee surgery, announced today that Fr...,s Board of Directors, effective August 24,2007. ... serves as the company,s Chief Executive Officer a...
...ollowing statement,is being released by Sr. Carol ...f the Catholic Health Association of the United St...eful for the clarification provided,today by the H...persistent vegetative state., The brief document,...
...errigo Company,(Nasdaq: PRGO ; TASE) today announ... Perrigo management team will provide a review of ...n Tuesday, September 18, 2007,beginning at 8:00 a....participant,code 10972. Presentations will be arch...
...chael Bond has,been named the VP Engineering for I...ny following nearly 30 years in various roles for ...Director of Blade Process,Engineering. Bond has a ...es. "The global markets we serve are expanding in...
...ork Services, Anti-Stigma Team in collaboration ...rity and County Commission...t. 17, 2007, 5:45 p.m., PONTIAC, Mich., Sept. 14 ...y will participate in the,upcoming "Uncovering The...
... in Medicare, WASHINGTON, Sept. 14 - The successf... saving the state of,Mississippi,s Medicaid progra...s article from Government Health IT. The savings a... Association,(PCMA) said today., "The state of Mi...
Other Medicine News:Health News:MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors 2Health News:Comment Regarding Congregation for the Doctrine of Faith Clarification Concerning Nutrition and Hydration for Patients in a Persistent Vegetative State 2Health News:Perrigo Company to Host Analyst Meeting on September 18, 2007 2Health News:Specialty Blades, Inc. Expands Management Team With New VP Engineering 2Health News:'UNCOVERING THE TRUTH - A Town Hall Meeting on Mental Health Parity' 2Health News:E-Prescribing Saving Mississippi Medicaid $1.2 Million Per Month 2
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
Medicine Products: